Table 3.
Cytotoxic activity on a patient-derived (PD) tumor cell line panel determined for compound 7h at 10 μM. Results are expressed by cellular growth inhibition percentage related to negative control.
| Tumor type | PD tumor cell line | % inhibition | Tumor type | PD tumor cell line | % inhibition |
|---|---|---|---|---|---|
| Stomach | GXF 251Lb | 55% | Breast | MAXF 401NL | 72% |
| GXA MKN45 | 8% | MAXF MDA231 | 67% | ||
| Colon | CXF DIFIb | 77% | MAXF MCF7 | 76% | |
| CXF Colo205 | 56% | Bladder | BXF 1218L | 84% | |
| CXF SW620 | 82% | BXF T24 | 76% | ||
| CXF RKO | 82% | Kidney | RXF 486L | 86% | |
| CXF HCT116 | 92% | RXF 786-O | 80% | ||
| Lung | LXFA PC9b | 75% | Glioblastoma | CNXF A172 | 86% |
| LXFA NCI-H1975c | 68% | Prostate | PRXF DU145 | 91% | |
| LXFL H460 | 33% | Uterus | UXF 1138L | 91% | |
| LXFL 529La | 74% | Liver | LIXF 575L | 40% | |
| LXFA 629L | 76% | Ovary | OVXF 899L | 87% | |
| Melanoma | MEXF 276L | 88% | Pancreas | PAXF 546L | 58% |
| MEXF 1737l | 15% | PAXF 1657l | 89% | ||
| MEXF 1539L | 93% | Sarcoma | SXF1301L | 89% |
aEGFR overexpressed, bEGFRdel-exon19 expressed, cEGFRwt expressed.